HomeCompareINDOY vs ABBV

INDOY vs ABBV: Dividend Comparison 2026

INDOY yields 3.13% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $78.8K in total portfolio value
10 years
INDOY
INDOY
● Live price
3.13%
Share price
$7.03
Annual div
$0.22
5Y div CAGR
-4.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.5K
Annual income
$243.51
Full INDOY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — INDOY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINDOYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INDOY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INDOY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INDOY
Annual income on $10K today (after 15% tax)
$266.00/yr
After 10yr DRIP, annual income (after tax)
$206.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,849.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INDOY + ABBV for your $10,000?

INDOY: 50%ABBV: 50%
100% ABBV50/50100% INDOY
Portfolio after 10yr
$62.9K
Annual income
$12,507.64/yr
Blended yield
19.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

INDOY
No analyst data
Altman Z
1.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INDOY buys
0
ABBV buys
0
No recent congressional trades found for INDOY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINDOYABBV
Forward yield3.13%3.06%
Annual dividend / share$0.22$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-4.1%40.6%
Portfolio after 10y$23.5K$102.3K
Annual income after 10y$243.51$24,771.77
Total dividends collected$2.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: INDOY vs ABBV ($10,000, DRIP)

YearINDOY PortfolioINDOY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,000$300.11$11,550$430.00$550.00ABBV
2$12,066$295.88$13,472$627.96$1.4KABBV
3$13,202$290.88$15,906$926.08$2.7KABBV
4$14,411$285.24$19,071$1,382.55$4.7KABBV
5$15,699$279.07$23,302$2,095.81$7.6KABBV
6$17,070$272.47$29,150$3,237.93$12.1KABBV
7$18,531$265.54$37,536$5,121.41$19.0KABBV
8$20,086$258.36$50,079$8,338.38$30.0KABBV
9$21,743$250.99$69,753$14,065.80$48.0KABBV
10$23,509$243.51$102,337$24,771.77$78.8KABBV

INDOY vs ABBV: Complete Analysis 2026

INDOYStock

Indorama Ventures Public Company Limited produces and distributes polyethylene terephthalate (PET), purified terephthalic acid (PTA), paraxylene, purified isophthalic acid, naphthalene dicarboxylate (NDC), integrated purified ethylene oxide and ethylene glycol, polyester, rayon, nylon, polypropylene, composites, and worsted wool fibers products. It operates in five segments: Integrated PET, Specialty Chemicals, Packaging, Integrated Oxides and Derivatives, and Fibers. The company offers various PET resins, including hot-fill, high and low intrinsic viscosity, quick heat, and general grade to serve beverage containers and food, pharmaceutical and household products, and industrial packaging applications, as well as produces clear and colored preforms, bottles, and closures. It also provides ethylene glycol used as a raw material in the production of polyester fibers, antifreeze, liquid coolant, and solvent; monoethylene glycol for use as a feedstock in the production of PET and polyester fibers; diethylene glycol used to manufacture polyester polyols, unsaturated polyester resins, buffet heaters, paints and coatings, plasticizers, liquid laundry detergents, and cement grinding; and triethylene glycol used for natural gas dehydration. In addition, the company offers surfactants, LAB, and ethanolamines used in manufacture of detergents, homecare products, soaps, toothpastes, shampoos, hair conditioners, and other foaming products. In addition, it provides polyester fibers and yarns used for apparels, home textile, automotive, and non-woven; bicomponent fibers; and worsted wool yarns used in making suits and sweaters, as well as tire cord yarns used in air bags and tire cords. The company operates in Thailand, North America, Europe, and internationally. The company was incorporated in 2003 and is headquartered in Bangkok, Thailand. Indorama Ventures Public Company Limited is a subsidiary of Indorama Resources Limited.

Full INDOY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this INDOY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INDOY vs SCHDINDOY vs JEPIINDOY vs OINDOY vs KOINDOY vs MAININDOY vs JNJINDOY vs MRKINDOY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.